Maven Capital Partners and YFM Equity Partners have completed a £6.5m Series A investment into Manchester-based BioTech innovator Biorelate.

Founded in 2014 and led by Daniel Jamieson, Biorelate curates dark biomedical knowledge to empower drug discovery with its proprietary AI platform, Galactic AI.

Galactic AI’s innovative technology uniquely combines natural language processing (NLP) and machine learning (ML) to capture highly valuable biomedical data that pharmaceutical and life sciences organisations can utilise to improve decision making in their drug discovery programs.

Jamieson, founder and CEO of Biorelate, said”Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics.

“Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies.

YFM invests £8m into MediaTech Wooshii

“Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions.”

Since launching Galactic AI™ in 2020, Biorelate has experienced significant growth and has brought on board leading global companies such as AstraZeneca and Idorsia, as well as a host of other undisclosed names.

The funding was raised through YFM’s VCTs, the Maven VCTs and Triple Point Ventures, with continued investment from NPIF – Maven Equity Finance, which is managed by Maven and part of the Northern Powerhouse Investment Fund, as well as a group of angel investors from the Manchester Tech Trust.

Biorelate will use the investment to increase its commercial and technical capacity, as well as wider expansion into the US to tap into the industry’s largest market.

Gavin Bell, investment director, led the deal for Maven. The YFM team included Andy Thomas, Aaron Lowery and Ian Waterfield.

Intelligence platform secures extra £3.4m investment

Bell said: “Biorelate has grown significantly since we first backed the business at an early stage through NPIF Maven Equity Finance. It’s exciting to see an innovative deep tech business born in Manchester now develop globally.

“We’re absolutely delighted to continue to support the vision and ambition of Dan and the Biorelate team, to scale and capitalise on the attractive global growth opportunities.”

Andy Thomas, partner at YFM Equity Partners, said: “Biorelate has the ability to be at the forefront of innovation in the pharmaceutical and life sciences industry. We are excited to be part of the next step in the business’ journey, and see huge potential for continued growth and expansion.”